Search Results - "ИММУНОСУПРЕССОРЫ"

1

Academic Journal

РОЛЬ ИММУНОМОДУЛИРУЮЩЕЙ ТЕРАПИИ В ЛЕЧЕНИИ И ПРОФИЛАКТИКЕ ЗАБОЛЕВАНИЙ У ДЕТЕЙ

Authors: Толипова Ноила Кудратовн, Латипова Шахноза Акбарбековна

Source: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 3 No. 6 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 251-255 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 3 № 6 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 251-255 ; 2181-3469

Subject Terms: Иммуномодуляторы, Детский иммунитет, Иммуностимуляторы, Хронические заболевания, Профилактика инфекций, Вакцинация, Респираторные инфекции, Иммуносупрессоры

File Description: application/pdf

Relation: https://sciencebox.uz/index.php/amaltibbiyot/article/view/11034/10072; https://sciencebox.uz/index.php/amaltibbiyot/article/view/11034

Availability: https://sciencebox.uz/index.php/amaltibbiyot/article/view/11034

View record from BASE

2

Academic Journal

Use of upadacitinib in a child with refractory ulcerative colitis ; Применение упадацитиниба у ребенка с рефрактерным течением язвенного колита

Authors: A. S. Potapov, A. E. Pushkareva, A. V. Vinokurova, M. O. Prokhorenkova, A. E. Krasnovidova, А. С. Потапов, А. Е. Пушкарева, А. В. Винокурова, М. О. Прохоренкова, А. Е. Красновидова

Source: Meditsinskiy sovet = Medical Council; № 13 (2024); 124-129 ; Медицинский Совет; № 13 (2024); 124-129 ; 2658-5790 ; 2079-701X

Subject Terms: упадацитиниб, Janus kinase inhibitor, targeted immunosuppressants, selective immunosuppressants, small molecules, biological therapy, upadacitinib, ингибитор янус-киназ, таргетные иммуносупрессоры, селективные иммунодепрессанты, малые молекулы, биологическая терапия

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8506/7477; Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(7):769-784. https://doi.org/10.1093/ecco-jcc/jjx009.; Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. https://doi.org/10.1136/bmj.j2505.; Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(8):989-997. https://doi.org/10.1093/ecco-jcc/jjw053.; Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7(1):e135. https://doi.org/10.1038/ctg.2015.63.; Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019;35(4):302-310. https://doi.org/10.1097/MOG.0000000000000536.; Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015;35(4):412-423. https://doi.org/10.1002/phar.1561.; Hajjat TM, Mosha M, Whaley KG, Rosen MJ, Suppa C, Markowitz J et al. Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study. Crohns Colitis 360. 2021;3(3):otab039. https://doi.org/10.1093/crocol/otab039.; Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719-729. https://doi.org/10.1038/nm.3895.; Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci. 2021;22(21):11322. https://doi.org/10.3390/ijms222111322.; De Vries LCS, Wildenberg ME, De Jonge WJ, D'Haens GR. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017;11(7):885-893. https://doi.org/10.1093/ecco-jcc/jjx003.; Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13(7):693-703. https://doi.org/10.1080/1744666X.2017.1291342.; Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1-8. https://doi.org/10.1016/j.phrs.2013.06.007.; Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023;83(4):299-314. https://doi.org/10.1007/s40265-023-01840-5.; Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(12):2010-2022. https://doi.org/10.1093/ibd/izab037.; Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020;158(8):2123-2138.e8. https://doi.org/10.1053/j.gastro.2020.01.047.; Irani M, Fan C, Glassner K, Abraham BP. Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes. Clin Exp Gastroenterol. 2023;16:21-28. https://doi.org/10.2147/CEG.S367086.; Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. https://doi.org/10.1016/S0140-6736(22)00581-5.; D'Haens G, Panes J, Louis E, Lacerda A, Zhou Q, Liu J, Loftus EV Jr. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. Clin Gastroenterol Hepatol. 2022;20(10):2337-2346.e3. https://doi.org/10.1016/j.cgh.2021.12.030.; Chugh R, Braga-Neto MB, Fredrick TW, Ramos GP, Terdiman J, El-Nachef N et al. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease. J Crohns Colitis. 2023;17(4):504-512. https://doi.org/10.1093/ecco-jcc/jjac157.; Miller M, Patel AS, Pasternak B. Rescue therapy with upadacitinib in medically refractory pediatric ulcerative colitis. JPGN Rep. 2024;5(2):197-199. https://doi.org/10.1002/jpr3.12067.; Kontaki E, Merchant A, Gaynor E, Kiparissi F. P494 Efficacy and safety of Upadacitinib in moderate to severe paediatric Crohn's disease and ulcerative colitis in a tertiary Paediatric IBD (PIBD) centre - A case series. J Crohns Colitis. 2024;18(1 Suppl.):i986. https://doi.org/10.1093/ecco-jcc/jjad212.0624.; Spencer EA, Bergstein S, Dolinger M, Pittman N, Kellar A, Dunkin D, Dubinsky MC. Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023:izad300. https://doi.org/10.1093/ibd/izad300.; Collen LV. Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease. Inflamm Bowel Dis. 2023;29(7):1175-1176. https://doi.org/10.1093/ibd/izad048.; Martinez-Vinson C, Lengliné H, Viala J. G-PP225 Upadacitinib: The Robert Debre Experience. JPGN Rep. 2024;5(1 Suppl.):S767. https://doi.org/10.1002/jpr3.12073.; Nedelkopoulou N, Sharma S. G-EPV158 Upadacitinib For Difficult-To-Treat Paediatric Ibd; A Single Centre Experience. JPGN Rep. 2024;5(1 Suppl.):S519. https://doi.org/10.1002/jpr3.12073.

Availability: https://www.med-sovet.pro/jour/article/view/8506
https://doi.org/10.21518/ms2024-281

View record from BASE

3

Academic Journal

POLYPHARMACY IN MANAGMENT OF IN-PATIENTS WITH NOVEL CORONAVIRUS DISEASE (COVID-19) ; ПОЛИПРАГМАЗИЯ ПРИ ЛЕЧЕНИИ СТАЦИОНАРНЫХ БОЛЬНЫХ С НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИЕЙ COVID-19

Authors: V. I. Petrov, A. Yu. Ryazanova, N. S. Privaltseva, D. A. Nekrasov, В. И. Петров, А. Ю. Рязанова, Н. С. Привальцева, Д. А. Некрасов

Contributors: This study did not receive any financial support from outside organizations., Данное исследование не имело финансовой поддержки от сторонних организаций.

Source: Pharmacy & Pharmacology; Том 10, № 3 (2022); 267-277 ; Фармация и фармакология; Том 10, № 3 (2022); 267-277 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2022-10-3

Subject Terms: лекарственно-индуцированное повреждение печени, COVID-19, ATC/DDD analysis, antibiotics, immunosuppressors, mucolytics, omeprazole, drug-induced liver injury, ATC/DDD анализ, антибиотики, иммуносупрессоры, муколитики, омепразол

File Description: application/pdf

Relation: https://www.pharmpharm.ru/jour/article/view/1119/857; https://www.pharmpharm.ru/jour/article/view/1119/854; Pazan F., Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences // Eur. Geriatr. Med. – 2021. – Vol. 12, No.3. – Р. 443–452. DOI:10.1007/s41999-021-00479-3.; Mangin D., Bahat G., Golomb B.A., Mallery L.H., Moorhouse P., Onder G., Petrovic M., Garfinkel D. International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action // Drugs Aging. – 2018. – Vol. 35, No. 7. – P. 575–587. DOI:10.1007/s40266-018-0554-2.; Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions // BMC Geriatr. – 2017. – Vol. 17. – Art. No.230. DOI:10.1186/s12877-017-0621-2.; Сычев Д.А., Отделенов В.А., Краснова Н.М., Ильина Е.С. Полипрагмазия: взгляд клинического фармаколога// Терапевтический архив. – 2016. – Т. 88, № 12. – С. 94–102. DOI:10.17116/terarkh2016881294-102.; Васькова Л.Б., Тяпкина М.В., Колосов В.В. Современная методология ВОЗ для оценки потребления лекарственных препаратов в стационаре // Ведомости Научного центра экспертизы средств медицинского применения. – 2012. – № 2. – С. 55–59.; Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFadden D.R., Soucy J.R., Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis // Clin. Microbiol. Infect. – 2020. – Vol. 26, No.12. – P. 1622–1629. DOI:10.1016/j.cmi.2020.07.016.; Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis // J. Infect. – 2020. – Vol. 81, No.2. – P. 266–275. DOI:10.1016/j.jinf.2020.05.046.; Петров В.И., Рязанова А.Ю., Пономарева А.В., Шаталова О.В., Левина Я.В. Клинико-экономический анализ потребления генно-инженерных биологических препаратов пациентами с COVID-19 // Фармация и фармакология. – 2022. – Т. 10, №2. – С. 198–206. DOI:10.19163/2307-9266-2022-10-2-198-206.; Langford B.J., So M., Raybardhan S., Leung V., Soucy J.R., Westwood D., Daneman N., MacFadden D.R. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis // Clin. Microbiol. Infect. – 2021. – Vol. 27, No.4. – P. 520–531. DOI:10.1016/j.cmi.2020.12.018.; Ye Q., Wang B., Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19 // J. Infect. – 2020. – Vol. 80, No.6. – P. 607–613. DOI:10.1016/j.jinf.2020.03.037.; Trougakos I.P., Stamatelopoulos K., Terpos E., Tsitsilonis O.E., Aivalioti E., Paraskevis D., Kastritis E., Pavlakis G.N., Dimopoulos M.A. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications // J. Biomed. Sci. – 2021. – Vol. 28. – Art. No.9. DOI:10.1186/s12929-020-00703-5.; Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey on polypharmacy and use of inappropriate medications // Toxicol. Int. – 2012. – Vol. 19, No.1. – P. 68–73. DOI:10.4103/0971-6580.94506.; Lin W.L., Muo C.S., Lin W.C., Hsieh Y.W., Kao C.H. Association of Increased Risk of Pneumonia and Using Proton Pump Inhibitors in Patients With Type II Diabetes Mellitus // Dose Response. – 2019. – Vol. 17, No.2. – Art. ID: 1559325819843383. DOI:10.1177/1559325819843383.; Hsu W.T., Lai C.C., Wang Y.H., Tseng P.H., Wang K., Wang C.Y., Chen L. Risk of pneumonia in patients with gastroesophageal reflux disease: A population-based cohort study // PLoS One. – 2017. – Vol.12, No.8. – Art. ID: e0183808. DOI:10.1371/journal.pone.0183808.; Hamai K., Iwamoto H., Ohshimo S., Wakabayashi Y., Ihara D., Fujitaka K., Hamada H., Ono K., Hattori N. Use of proton pump inhibitors is associated with increased mortality due to nosocomial pneumonia in bedridden patients receiving tube feeding // Geriatr. Gerontol. Int. – 2018. – Vol. 18, No.8. – P. 1215–1218. DOI:10.1111/ggi.13450.; Almario C.V., Chey W.D., Spiegel B.M.R. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors // Am. J. Gastroenterol. – 2020. – Vol. 115, No.10. – P. 1707–1715. DOI:10.14309/ajg.0000000000000798.; Conrad K.P. Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology? // Physiol. Rep. – 2021. – Vol. 8, No.24. – Art. ID: e14649. DOI:10.14814/phy2.14649.; Hariyanto T.I., Prasetya I.B., Kurniawan A. Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection // Dig. Liver Dis. – 2020. – Vol. 52, No.12. – P. 1410–1412. DOI:10.1016/j.dld.2020.10.001.; Kow C.S., Hasan S.S. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis // J. Intern. Med. – 2021. – Vol. 289, No.1. – P. 125–128. DOI:10.1111/joim.13183.; Lee S.W., Ha E.K., Yeniova A.Ö., Moon S.Y., Kim S.Y., Koh H.Y., Yang J.M., Jeong S.J., Moon S.J., Cho J.Y., Yoo I.K., Yon D.K. Severe Clinical Outcomes of COVID-19 Associated with Proton Pump Inhibitors: a Nationwide Cohort Study with Propensity Score Matching // Gut. – 2020. – Vol. 70, No.1. – P. 76–84. DOI:10.1136/gutjnl-2020-322248.; Lee S.W., Yang J.M., Yoo I.K., Moon S.Y., Ha E.K., Yeniova A.Ö., Cho J.Y., Kim M.S., Shin J.I., Yon D.K. Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort // Gut. – 2021. – Vol. 70, No.10. – P. 2013–2015. DOI:10.1136/gutjnl-2020-323672.; Luxenburger, H., Sturm, L., Biever, P., Rieg, S., Duerschmied, D., Schultheiss, M., Neumann-Haefelin C., Thimme R., Bettinger D. Treatment with Proton Pump Inhibitors Increases the Risk of Secondary Infections and ARDS in Hospitalized Patients with COVID-19: Coincidence or Underestimated Risk Factor? // J. Intern. Med. – 2021. – Vol. 289, No.1. – P. 121–124. DOI:10.1111/joim.13121.; Janowitz T., Gablenz E., Pattinson D., Wang T.C., Conigliaro J., Tracey K., Tuveson D. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series // Gut. – 2020. – Vol. 69, No.9. – P. 1592–1597. DOI:10.1136/gutjnl-2020-321852.; Freedberg D.E., Conigliaro J., Wang T.C., Tracey K.J., Callahan M.V., Abrams J.A.; Famotidine Research Group. Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study // Gastroenterology. – 2020. – Vol. 159, No.3. – P. 1129–1131.e3. DOI:10.1053/j.gastro.2020.05.053.; Samimagham H.R., Hassani Azad M., Haddad M., Arabi M., Hooshyar D., KazemiJahromi M. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial // Trials. – 2020. – Vol. 21, No.1. – Art. No.848. DOI:10.1186/s13063-020-04773-6.; Mather J.F., Seip R.L., McKay R.G. Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19 // Am. J. Gastroenterol. – 2020. – Vol. 115, No.10. – P. 1617–1623. DOI:10.14309/ajg.0000000000000832.; Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., Wang Q., Xu Y., Li M., Li X., Zheng M., Chen L., Li H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods // Acta Pharm. Sin. B. – 2020. – Vol. 10, No.5. – P. 766–788. DOI:10.1016/j.apsb.2020.02.008.; Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work // Nat. Med. – 2020. DOI:10.1038/d41591-020-00019-9.; Loffredo M., Lucero H., Chen D.Y., O’Connell A., Bergqvist S., Munawar A., Bandara A., De Graef S., Weeks S.D., Douam F., Saeed M., Munawar A.H. The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication // Sci. Rep. – 2021. – Vol. 11, No.1. – Art. ID: 5433. DOI:10.1038/s41598-021-84782-w.; Chiu L, Shen M, Lo CH, Chiu N, Chen A, Shin HJ, Prsic EH, Hur C, Chow R, Lebwohl B. Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis // PLoS One. – 2021. – Vol. 16, No.11. – Art. ID: e0259514. DOI:10.1371/journal.pone.0259514.; Kehinde I.A., Egbejimi A., Kaur M., Onyenaka C., Adebusuyi T., Olaleye O.A. Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2 // J. Mol. Graph. Model. – 2022. – Vol. 114. – Art. ID: 108201. DOI:10.1016/j.jmgm.2022.108201.; Carpinteiro F., Gripp B., Hoffmann V., Pöhlmann S., Hoertel N., Edwards M.J., Kamler M., Kornhuber J., Becker K.A., Gulbins E. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells // J. Biol. Chem. – 2021. – Vol. 296. DOI:10.1016/j.jbc.2021.100701.; Di Marco F., Foti G., Corsico A.G. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19? // Eur. Rev. Med. Pharmacol. Sci. – 2022. – Vol. 26, No.2. – P. 715–721. DOI:10.26355/eurrev_202201_27898.; Faverio P., Rebora P., Rossi E., Del Giudice S., Montanelli F., Garzillo L., Busnelli S., Luppi F., Valsecchi M.G., Pesci A. Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study // ERJ Open Res. – 2021. – Vol. 8, No.1. – Art. ID: 00542–2021. DOI:10.1183/23120541.00542-2021.; Симонова О.И. Муколитики для детей при ОРИ: от теории к практике // Фарматека. – 2017. – №4 (337). – C. 16–22.; Brahma D., Marak M., Wahlang J. Rational Use of Drugs and Irrational Drug Combinations // The Internet Journal of Pharmacology. – 2012. – Vol. 10. – P. 1–5. DOI:10.5580/2b59.; Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., Sun Y., Liu Y., He Q., Chen J., Liu L., Xu L. COVID-19: Abnormal liver function tests // J. Hepatol. – 2020. – Vol. 73, No.3. – P. 566–574. DOI:10.1016/j.jhep.2020.04.006.; Xie H., Zhao J., Lian N., Lin S., Xie Q., Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study // Liver Int. – 2020. – Vol. 40, No.6. – P. 1321–1326. DOI:10.1111/liv.14449.; Fan Z., Chen L., Li J., Cheng X., Yang J., Tian C., Zhang Y., Huang S., Liu Z., Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality // Clin. Gastroenterol. Hepatol. – 2020. – Vol. 18, No.7. – P. 1561–1566. DOI:10.1016/j.cgh.2020.04.002.; Yadav D.K., Singh A., Zhang Q., Bai X., Zhang W., Yadav R.K., Singh A., Zhiwei L., Adhikari V.P., Liang T. Involvement of liver in COVID-19: systematic review and meta-analysis // Gut. – 2021. – Vol. 70, No.4. – P. 807–809. DOI:10.1136/gutjnl-2020-322072.; https://www.pharmpharm.ru/jour/article/view/1119

Availability: https://www.pharmpharm.ru/jour/article/view/1119
https://doi.org/10.19163/2307-9266-2022-10-3-267-277

View record from BASE

4

Academic Journal

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis ; Предикторы отмены генно-инженерных биологических препаратов ввиду развития нежелательных явлений у пациентов с ревматоидным артритом

Authors: E. N. Koltsova, G. V. Lukina, E. I. Schmidt, K. A. Lytkina, E. V. Zhilyaev, Е. Н. Кольцова, Г. В. Лукина, Е. И. Шмидт, К. A. Лыткина, Е. В. Жиляев

Source: Modern Rheumatology Journal; Том 16, № 6 (2022); 26-31 ; Современная ревматология; Том 16, № 6 (2022); 26-31 ; 2310-158X ; 1996-7012

Subject Terms: инфекционные осложнения, biologic disease modifying antirheumatic drugs, targeted immunosuppressive agents, adverse events, infectious complications, генно-инженерные биологические препараты, таргетные иммуносупрессоры, нежелательные явления

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1368/1308; Муравьев ЮВ, Гриднева ГИ, Муравьева ЛА и др. Основания для отмены базисных противовоспалительных препаратов, генно-инженерных биологических препаратов и тофацитиниба при ревматоидном артрите. Современная ревматология. 2018; 11(4):101-5. doi:10.14412/1996-7012-2018-4-101-105; Муравьев ЮВ. Какие неблагоприятные реакции на генно-инженерные биологические препараты относят к парадоксальным? Научно-практическая ревматология. 2018;56(4):531-4.; Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008 Mar;35(3):387-93. Epub 2008 Feb 1.; Van Vollenhoven RF, Emery P, Bingham CO3rd. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial program with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013 Sep 1;72(9):1496-502. doi:10.1136/annrheumdis-2012-201956. Epub 2012 Nov 7.; Quartuccio L. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. Journal of Advanced Research. 2019;15:87-93.; Simon TA, Askling J, Lacaille D. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther. 2010;12(2): R67. doi:10.1186/ar2984. Epub 2010 Apr 14.; Souto A, Maneiro JR, Gуmez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016 Mar;55(3):523-34. doi:10.1093/rheumatology/kev374. Epub 2015 Oct 21.; Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a metaanalysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208-32. doi:10.1016/j.amjmed.2014.06.012. Epub 2014 Jun 17.; Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun; 76(6):1101-36. doi:10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15.; Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010 Sep;62(9): 2625-32. doi:10.1002/art.27555.; Askling J, CM Fored, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007 Oct;66(10):1339-44. doi:10.1136/ard.2006.062760. Epub 2007 Jan 29.; Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011 Apr;70(4):616-23. doi:10.1136/ard.2010.137422. Epub 2010 Dec 21.; Singh JA, Wells GA, Christensen R. Adverse effects of biologics: a network metaanalysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;2011(2): CD008794. doi:10.1002/14651858.CD008794.pub2.; Carrara G, Bortoluzzi A, Sakellariou G, et al. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clin Exp Rheumatol. 2019 Jan-Feb;37(1):60-6. Epub 2018 Jul 18.; Iwanaga N, Arima K, Terada K, et al. Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study. Int J Rheum Dis. 2017 Mar;20(3):346-52. doi:10.1111/1756-185X.12348. Epub 2014 Apr 10.; Machado MAA, de Moura CS, Guerra SF, et al. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther. 2018 Mar 23;20(1):60. doi:10.1186/s13075-018-1539-6.; Cecconi M, Ranza R, Titton DC, et al. Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondy-loarthritis on Biologic Drugs-Data From the Brazilian Registry for Biologics Monitoring. J Clin Rheumatol. 2020 Mar;26(2):73-8. doi:10.1097/RHU.0000000000000935.; Lampropoulos CE, Orfanos P, Bournia VK. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):216-24. Epub 2015 Feb 9.; Sakai R, Cho SK, Nanki T, et al. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther. 2015 Mar 23;17(1):74. doi:10.1186/s13075-015-0583-8.; Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015 Jul 18;386(9990):258-65. doi:10.1016/S0140-6736(14)61704-9. Epub 2015 May 11.; Canete JD, Hernandez MV, Sanmarti R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin Biol Ther. 2017 Sep;17(9):1089-103. doi:10.1080/14712598.2017.1346078. Epub 2017 Jul 17.; Leon L, Gomez A, Vadillo C. Severe adverse drug reactions to biological diseasemodifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol. 2018 Jan-Feb; 36(1):29-35. Epub 2017 Jun 6.; Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adali-mumab, etanercept and infliximab. Ann Rheum Dis. 2015 Feb;74(2):354-60. doi:10.1136/annrheumdis-2013-204128. Epub 2013 Nov 27.

Availability: https://mrj.ima-press.net/mrj/article/view/1368
https://doi.org/10.14412/1996-7012-2022-6-26-31

View record from BASE

5

Academic Journal

Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study ; Реальная практика лекарственной терапии среднетяжелых и тяжелых форм воспалительных заболеваний кишечника в России, Республике Беларусь и Республике Казахстан. Промежуточные результаты исследования INTENT

Authors: Knyazev O.V., Belousova E.A., Abdulganieva D.I., Gubonina I.V., Kaibullayeva J.A., Marakhouski Y.K., Chashkova E.Y., Shapina M.V., Shchukina O.B., Gegenava B.B., Oliferuk N.S.

Source: Almanac of Clinical Medicine; Vol 49, No 7 (2021); 443-454 ; Альманах клинической медицины; Vol 49, No 7 (2021); 443-454 ; 2587-9294 ; 2072-0505

Subject Terms: inflammatory bowel diseases, Crohn's disease, ulcerative colitis, epidemiology, medical treatment, real world clinical practice, 5-aminosalicylic acid, glucocorticosteroids, immunosuppressants, genetically engineered biological agents, vedolizumab, воспалительные заболевания кишечника, болезнь Крона, язвенный колит, эпидемиология, лекарственная терапия, реальная клиническая практика, 5-аминосалициловая кислота, глюкокортикостероиды, иммуносупрессоры, генно-инженерные биологические препараты, ведолизумаб

File Description: application/pdf

Availability: https://almclinmed.ru/jour/article/view/1619
https://doi.org/10.18786/2072-0505-2021-49-061

View record from BASE

6

Academic Journal

THE ANESTHESIA FEATURES UNDER ABDOMINAL BIRTH OF THE WOMEN WITH A TRANSPLANT KIDNEY ; ОСОБЕННОСТИ АНЕСТЕЗИИ ПРИ АБДОМИНАЛЬНОМ РОДОРАЗРЕШЕНИИ ЖЕНЩИН С ТРАНСПЛАНТИРОВАННОЙ ПОЧКОЙ

Authors: A. Yu. Korolev, A. V. Pyregov, А. Ю. Королёв, А. В. Пырегов

Source: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 12, № 3 (2015); 43-47 ; Вестник анестезиологии и реаниматологии; Том 12, № 3 (2015); 43-47 ; 2541-8653 ; 2078-5658

Subject Terms: immunosuppressant, abdominal birth, anesthesia, transplant kidney, абдоминальное родоразрешение, анестезия, трансплантированная почка, иммуносупрессоры, pregnancy

File Description: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/30/93; Кулаков В. И., Мурашко Л. Е., Мойсюк Я. Г. Беременность и роды у женщин с пересаженной почкой // Акуш. и гинекол. - 2004. - № 2. - С. 27-32.; Тикко О. Случай успешной беременности у женщины с пересаженной почкой // Ж. клин. случ. и наблюден. www.critical.ru; Beena K. P., Veena R. S. Anesthesia for parturient with renal transplantation // J. Anaesthesiology Clin. Pharmacol. - 2012. - Vol. 28, № 4. - P. 524-527.; Cyganek A., Wiczy Е. Jabiry-Zieniewicz Z. et al. Pregnancy delivery and newborn in female kidney recipients // Ginekology Pol. - 2011. - № 72. - P. 1287-1290.; Dębska-Ślizień A., Gałgowska J., Chamienia A. Pregnancy after kidney transplantation: a single-center experience and review of the literature // Transplant Proc. - 2014. - № 46. - P. 2668-2672.; EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient // Nephrol. Dial. Transplant. - 2002. - Vol. 17, № 4. - P. 1-67.; Gyamlani G., Geraci S. A. Kidney disease in pregnancy: (Women’s Health Series) // South Med. J. - 2013. - Vol. 106, № 9. - P. 519-525.; Hooi L. S., Rozina G., Shaariah M. Y. Pregnancy in patients with renal transplants in Malaysia // Med. J. Malaysia. - 2003. - № 58. - P. 27-35.; Modi M. P., Vora K. S., Parikh G. P. Anesthetic management in parturients with chronic kidney disease undergoing elective Caesarean delivery: Our experience of nine cases // Indian. J. Nephrol. - 2014. - Vol. 24, № 1. - P. 20-23.; Norrman E., Bergh C., Wennerholm U. Pregnancy outcome and long-term follow-up after in vitro fertilization in women with renal transplantation // Hum. Reprod. - 2015. - Vol. 30, № 1. - P. 205-213.; Rupley D., Janda A. M., Kapeles S. R. et al. Preconception counseling, fertility, and pregnancy complications after abdominal organ transplantation: a survey and cohort study of 532 recipients // Clin. Transplant. - 2014. - Vol. 28, № 9. - P. 937-945.; Sicard A., Amrouche L., Suberbielle C. et al. Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology // Am. J. Transplant. - 2014. - Vol. 14, № 1. - P. 193-201.; Songin T., Pietrzak B., Brawura-Biskupski-Samaha R. et al. Pregnancy after kidney and liver transplantation: its outcome and effect on the graft, mother, and neonate // Ann. Transplantation. - 2014. - Vol. 19. - P. 660-666.; Stratta P., Canavese C., Giacchino F. et al. Pregnancy in kidney transplantation: satisfactory outcomes and harsh realities // J. Nephrology - 2003. - № 16. - P. 792-806.; Wallace C. J., Kingsmore D. B. Transplantation and immunosuppressive therapy // Anaesth. Int. Care Med. - 2006. - Vol. 7. - P. 196.; Wyld M., Clayton P. A., Jesudason S. et al. Pregnancy outcomes for kidney transplant recipients // Am. J. Transplantation. - 2013. - Vol. 13, issue 12. - P. 3173-3182.

Availability: https://www.vair-journal.com/jour/article/view/30
https://doi.org/10.21292/2078-5658-2015-12-3-43-47

View record from BASE

7

Academic Journal